



(51) International Patent Classification:

C07D 471/20 (2006.01) **A61K 31/435** (2006.01)
C07D 519/00 (2006.01)

(21) International Application Number:

PCT/IB2011/054643

(22) International Filing Date:

18 October 2011 (18.10.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/408,127 29 October 2010 (29.10.2010) US
61/531,744 7 September 2011 (07.09.2011) US

(71) Applicant (for all designated States except US): **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BAGLEY, Scott William** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **DOW, Robert Lee** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **GRIFFITH, David Andrew** [US/US]; Pfizer Global Research and Development, 87 Cambridge Park Drive, Cambridge, Massachusetts 02140 (US). **SMITH, Aaron Christopher** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US).

(74) Agent: **BENSON, Gregg C.**; Pfizer Inc., Eastern Point Road, MS9114, Groton, Connecticut 06340 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).





Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS



(57) Abstract: The invention provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof; wherein G is Formula (II), Formula (III), Formula (IV) and Formula (V) R¹, R² and R³ are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.